Initial Management of T4 Invasive Lobular Breast Carcinoma
Rationale for Neoadjuvant Chemotherapy
- Primary systemic therapy (neoadjuvant chemotherapy) is specifically indicated for locally advanced breast cancer (stage IIIA, IIIB, IIIC), which includes T4 tumors, according to the European Society for Medical Oncology 1, 2
- The goal of neoadjuvant therapy in T4 disease is to downstage the tumor to potentially allow for surgical resection, as recommended by the American Society of Clinical Oncology 3
- Neoadjuvant therapy also assesses tumor response to systemic therapy, providing prognostic information, and potentially increases the likelihood of breast conservation in select cases, as suggested by the National Comprehensive Cancer Network 3
Important Considerations for T4 Invasive Lobular Carcinoma
- Before initiating neoadjuvant chemotherapy, a core biopsy for histology and analysis of predictive factors (ER, PR, HER2) should be performed, as recommended by the European Society for Medical Oncology 2
- Full clinical staging to rule out metastatic disease is necessary in T4 disease, according to the American Joint Committee on Cancer 2
- Axillary dissection is typically performed rather than sentinel node biopsy alone in T4 disease, as recommended by the Society of Surgical Oncology 2
Treatment Sequence for T4 Invasive Lobular Carcinoma
- All planned treatment should be delivered without unnecessary breaks, regardless of tumor response, as recommended by the European Society for Medical Oncology 4
- Choice of chemotherapy regimen should be based on tumor biology (ER/PR status, HER2 status), according to the National Comprehensive Cancer Network 3
- Breast-conserving surgery is generally contraindicated in T4 tumors, as recommended by the American Society of Breast Surgeons 1, 2
Post-Surgical Treatment
- Adjuvant radiation therapy is indicated following surgery for T4 disease, as recommended by the American Society for Radiation Oncology 4
- For hormone receptor-positive disease, adjuvant endocrine therapy is recommended, according to the National Comprehensive Cancer Network 3
- For HER2-positive disease, adjuvant trastuzumab should be considered, as suggested by the American Society of Clinical Oncology 3
Special Considerations for Invasive Lobular Carcinoma
- Invasive lobular carcinoma is often more diffuse in the breast, which can make assessment of tumor extent challenging, as noted by the American Cancer Society 5, 6
- Complete excision with negative margins is essential when planning surgical management, as recommended by the Society of Surgical Oncology 5, 6